

Neuralstem, Inc.  
Form 8-K  
June 26, 2012

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 26, 2012 (June 25, 2012)**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

|   |                              |  |
|---|------------------------------|--|
| Delaware  | 000-1357459                  | 52-2007292                               |
| <b>(State or other jurisdiction of<br/>incorporation or organization)</b> | <b>(Commission File No.)</b> | <b>(IRS Employee Identification No.)</b> |

**9700 Great Seneca Highway, Rockville, Maryland 20850**

**(Address of Principal Executive Offices)**

**(301) 366-4841**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On June 25, 2012, Neuralstem, Inc. (“Company”) announced that the first patients were dosed in the Phase Ib portion of the Company’s ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit**

Description

**Number**

99.01 Press Release Dated June 25, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr  
Chief Executive Officer

Dated: June 26, 2012